Skip to main content

Advertisement

SpringerLink
Log in

Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil

  • Letter to the Editor
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

5FU:

5-Flourouracil

DPD:

Dihydropyrimidine dehydrogenase

FOLFOX:

Leucovorin + 5FU + Oxaliplatin

References

  1. Kodali S, Bathini V, Rava P, Tipirneni E. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-fluorouracil. J Gastrointest Cancer. 2016

  2. Terrazzino S, Cargnin S, Del RM, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14 + 1G > A and 2846A > T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14(11):1255–72.

    Article  CAS  PubMed  Google Scholar 

  3. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32(10):1031–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227–34.

    Article  CAS  PubMed  Google Scholar 

  5. Lunenburg CA, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer. 2016;54:40–8.

    Article  PubMed  Google Scholar 

  6. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–14.

    Article  CAS  PubMed  Google Scholar 

  7. Swen JJ, Nijenhuis M, De BA, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73.

    Article  CAS  PubMed  Google Scholar 

  8. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94(6):640–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Background information pharmacogenetics—dihydropyrimidine dehydrogenase (DPD). 2016; Available from: http://www.kennisbank.knmp.nl. 2015

  10. Magnani E, Farnetti E, Nicoli D, et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med. 2013;8(5):417–23.

    Article  PubMed  Google Scholar 

  11. Bank PCD, Guchelaar HJ, Swen JJ. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule. Intern Emerg Med. 2014;9(4):481–2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, Post zone C7-P, 2300 RC, Leiden, The Netherlands

    CATC Lunenburg & H Gelderblom

  2. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands

    JJ Swen & H-J Guchelaar

Authors
  1. CATC Lunenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JJ Swen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H-J Guchelaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Gelderblom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Gelderblom.

Ethics declarations

Conflict of Interest

The authors declare no conflict of interest. CL was supported by an unrestricted grant from Roche Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lunenburg, C., Swen, J., Guchelaar, HJ. et al. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil. J Gastrointest Canc 48, 117–118 (2017). https://doi.org/10.1007/s12029-016-9908-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-016-9908-3

Keywords

Search

Navigation